EUVIMEDEUVIMED entdecken
Open Access

CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer

Cinzia Imberti, Roberto De Gregorio, Joshua A Korsen, Tran T Hoang, Samantha Khitrov, Teja Kalidindi, Subhiksha Nandakumar, Jooyoung Park, Samir Zaidi, Naga Vara Kishore Pillarsetty, Jason S Lewis

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.267107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Cinzia Imberti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron-Emission Tomography, Receptors, Androgen, GPI-Linked Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of androgen receptor (AR)-negative (AR-) prostate cancer, including aggressive neuroendocrine prostate cancer (NEPC), has more than doubled in the last decade, but its timely diagnosis is difficult as it lacks typical prostate cancer hallmarks. The carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) has recently been identified as an upregulated surface antigen in NEPC. We developed an immuno-PET agent targeting CEACAM5 and evaluated its ability to delineate AR- prostate cancer in vivo.

Methods

CEACAM5 expression was evaluated in a panel of prostate cancer cell lines by immunohistochemistry and Western blotting. The CEACAM5-targeting antibody labetuzumab was conjugated with the chelator desferrioxamine (DFO) and radiolabeled with 89Zr. The in vivo distribution of the radiolabeled antibody was evaluated in xenograft prostate cancer models by PET imaging and ex vivo organ distribution.

Results

The NEPC cell line H660 exhibited strong CEACAM5 expression, whereas expression was limited in the AR- cell lines PC3 and DU145 and absent in the AR-positive cell line LNCaP. [89Zr]Zr-DFO-labetuzumab imaging was able to clearly delineate both neuroendocrine H660 xenografts and AR- DU145 in vivo but could not detect the AR-positive xenograft LNCaP.

Conclusion

Immuno-PET imaging with [89Zr]Zr-DFO-labetuzumab is a promising diagnostic tool for AR- prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron-Emission TomographyReceptors, AndrogenGPI-Linked ProteinsMaleHumansCell Line, TumorAnimalsMiceAntigens, CDZirconiumTissue DistributionCell Adhesion MoleculesRadioisotopesCarcinoembryonic Antigen

Stichwörter der Autor:innen

CEACAM5androgen receptor–negative prostate cancerimmuno-PETmolecular imaging

Substanzen

Receptors, AndrogenGPI-Linked ProteinsCEACAM5 protein, humanAntigens, CDZirconiumCell Adhesion MoleculesZirconium-89RadioisotopesCarcinoembryonic Antigen

Autor:innen und Institutionen

  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pharmacology, Weill Cornell Medicine, New York, New York.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
  • Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Imberti, C., De Gregorio, R., Korsen, J. A., Hoang, T. T., Khitrov, S., Kalidindi, T., Nandakumar, S., Park, J., Zaidi, S., Pillarsetty, N. V. K., & Lewis, J. S. (2024). CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267107

Vancouver

Imberti C, De Gregorio R, Korsen JA, Hoang TT, Khitrov S, Kalidindi T, et al. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267107

BibTeX
@article{Imberti2024,
  author = {Imberti, Cinzia and De Gregorio, Roberto and Korsen, Joshua A and Hoang, Tran T and Khitrov, Samantha and Kalidindi, Teja and Nandakumar, Subhiksha and Park, Jooyoung and Zaidi, Samir and Pillarsetty, Naga Vara Kishore and Lewis, Jason S},
  title = {CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.267107}
}
Kostenlos starten →